S.B. No. 3005 is a legislative proposal that mandates the Texas Department of State Health Services to conduct a comprehensive study on the use of psychedelic therapies, specifically MDMA, psilocybin, and ketamine, for treating mental health conditions such as post-traumatic stress disorder (PTSD) and depression. The study will involve a review of clinical trials, current literature, and actions taken by the U.S. Food and Drug Administration regarding these therapies. Additionally, the department will evaluate treatment guidelines and patient access to these therapies, recommending necessary legislative or other actions to ensure accessibility following FDA approval.

The bill requires the department to submit a written report by December 1, 2026, detailing the study's findings and any recommendations for legislative action to facilitate patient access to psychedelic therapies. The act is set to expire on September 1, 2027, and will take effect on September 1, 2025.